Gastrointestinal Stromal Tumor

While imatinib revolutionized first-line therapy, resistance and specific mutation profiles necessitate subsequent generations of tyrosine kinase inhibitors (TKIs). Second- and third-generation TKIs have transformed the management of advanced GIST, extending survival and offering mutation-specific precision therapy. Ongoing research into resistance mechanisms, combination strategies, and novel inhibitors promises further optimization of patient-centered care.

Furthermore, patients with high serum IgG levels experienced significant therapeutic benefits. Our data show that local adaptive immunity dominated by TLS is a key factor in the efficacy of targeted therapy, and suggest that inducing IgG could be a feasible strategy for improving the prognosis of patients with GIST.

Western blot and qRT-PCR tests validated these genes in GIST-T1 cells, and ssGSEA analysis indicated a significant relationship between these hub genes and immune cell infiltration. This study revealed a set of novel signature genes with high diagnostic value, offering promising targets for the diagnosis and treatment of GIST.

Because of failure of imatinib therapy and multiple transarterial embolization procedures, sunitinib therapy was initiated, stabilizing the disease for nine months. Sunitinib therapy in NF1 patients requires strict blood pressure control. Additionally, pre-treatment vascular screening with CT angiography may be warranted.

This is the first reported case of PF resected by planned LECS following preoperative diagnosis by bite-on-bite biopsy. LECS offers a safe and effective option for managing PF and other submucosal tumors in anatomically sensitive locations.

Imatinib normalized calcium and parathyroid hormone levels and induced tumor regression...4D-CT and FCH-PET/CT can be used as alternative imaging modalities following 99mTc-sestamibi SPECT/CT to locate ectopic parathyroid lesions. The mechanism behind GIST-related hypercalcemia may involve the expression of PTHrP or 1-alpha-hydroxylase in tumor tissues.

In some cases, targeted therapy with drugs such as imatinib may be used before or after surgery to shrink the tumor or prevent its recurrence...Patient was treated with targeted therapy and surgery that resulted in excellent outcome with prolonged survival. Although esophageal GIST is a rare scenario, outcome in this subset of patients can be improved with the use of targeted therapy that hasten the symptomatic relief and adds to survival benefit.

Tumor size and Ki-67 were associated with malignancy in this exploratory multivariable analysis, but these findings should be interpreted with caution due to limited follow-up and sample imbalance. Combined with CD117/DOG1 profiling, they enhance diagnostic accuracy and may inform diagnostic assessment; however, prognostic implications require outcome-based studies.

First-generation sequencing identified concurrent mutations in c-KIT exons 11 (V560D) and exon 17 (N822K), implicating these double mutations in acquired imatinib resistance. This case underscores the clinical significance of double mutations in GIST, the limitations of first-line therapy in such contexts, and the importance of early genetic profiling to inform personalized treatment strategies.

The consensus made 24 recommendations: gliomas in the optic pathway-6 statements, non-optical gliomas-2 statements, plexiform neurofibromas-5 statements, malignant peripheral nerve sheath tumors (MPNST)-6 statements, melanoma-1 statement, juvenile myelomonocytic leukemia (JMML)-1 statement, pheochromocytoma and paraganglioma-2 statements, and gastrointestinal stromal tumors (GIST)-1 statement. This consensus represents the first Brazilian recommendations on malignant and benign tumors in pediatric patients with NF1, providing a framework to standardize and optimize the clinical application for this disease.

The patient was treated with imatinib, resulting in marked reduction in tumor size and improvement in urinary symptoms. This case highlights the importance of considering rectal GIST in the differential diagnosis of prostatic masses, especially in patients with atypical clinical and imaging findings.

P3, N=450, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting